Plus Therapeutics (NASDAQ:PSTV) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Thursday,Benzinga reports. The brokerage currently has a $3.00 target price on the stock.

A number of other analysts have also issued reports on PSTV. Lake Street Capital assumed coverage on shares of Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $1.00 target price (down from $2.00) on shares of Plus Therapeutics in a research note on Friday, January 23rd. Finally, Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, November 21st. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.60.

Plus Therapeutics Stock Up 2.2%

PSTV stock opened at $0.24 on Thursday. The stock’s 50 day moving average is $0.29 and its two-hundred day moving average is $0.47. Plus Therapeutics has a 52-week low of $0.16 and a 52-week high of $2.08. The company has a market capitalization of $41.36 million, a PE ratio of -0.19 and a beta of 0.79.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the second quarter valued at $41,000. Susquehanna International Group LLP acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the 3rd quarter valued at about $100,000. XTX Topco Ltd bought a new stake in shares of Plus Therapeutics during the 4th quarter worth about $127,000. Finally, State Street Corp lifted its stake in shares of Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after acquiring an additional 127,000 shares during the period. Institutional investors and hedge funds own 3.28% of the company’s stock.

Key Plus Therapeutics News

Here are the key news stories impacting Plus Therapeutics this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set a $3.00 price target (very large upside vs. recent levels), a loud bullish signal that can attract speculative buying and broader investor interest. Benzinga
• Positive Sentiment: Plus published a health-economics analysis presented at ISPOR showing CNSide may reduce healthcare costs for leptomeningeal metastases by ~40% and emphasized value of earlier diagnosis as it enters U.S. commercialization — a commercial/economic data point that could support pricing, payer conversations and launch uptake. GlobeNewswire: CNSide ISPOR Analysis
• Neutral Sentiment: The company is scheduled to release quarterly earnings this week — a routine catalyst that could drive volatility depending on guidance and cash-burn metrics. Plus Therapeutics to Release Quarterly Earnings
• Neutral Sentiment: Broker coverage updates and long-horizon forecasts (FY2030) were published, which may shape investor expectations but are distant and model-dependent. Brokers Issue Forecasts for PSTV FY2030 Earnings
• Negative Sentiment: HC Wainwright trimmed near-term quarterly EPS estimates (several Q1–Q4 2026 cuts to ~$-0.04) while keeping a Buy rating and a $1.00 target — the downward near-term revisions highlight persistent losses and raise the importance of upcoming commercial execution and cash management. MarketBeat: HC Wainwright Notes

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.